129 related articles for article (PubMed ID: 34955547)
21. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations.
Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ
Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930
[TBL] [Abstract][Full Text] [Related]
22. BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma.
Affolter K; Samowitz W; Tripp S; Bronner MP
Genes Chromosomes Cancer; 2013 Aug; 52(8):748-52. PubMed ID: 23650027
[TBL] [Abstract][Full Text] [Related]
23. Demographic trends and KRAS/BRAF
Fu X; Huang Y; Fan X; Deng Y; Liu H; Zou H; Wu P; Chen Z; Huang J; Wang J; Lin H; Huang S; Tan X; Lan P; Wang L; Wang JP
Int J Cancer; 2019 May; 144(9):2109-2117. PubMed ID: 30414169
[TBL] [Abstract][Full Text] [Related]
24. Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer.
Osumi H; Shinozaki E; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Takahari D; Ooki A; Suzuki T; Ota Y; Nakayama I; Chin K; Miki Y; Yamaguchi K
Int J Cancer; 2019 Nov; 145(9):2488-2495. PubMed ID: 30963570
[TBL] [Abstract][Full Text] [Related]
25. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
[TBL] [Abstract][Full Text] [Related]
26. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer.
Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA
Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523
[TBL] [Abstract][Full Text] [Related]
27. A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
Zhu YC; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G; Lv TF; Song Y
Clin Lung Cancer; 2019 May; 20(3):e224-e228. PubMed ID: 30914311
[No Abstract] [Full Text] [Related]
28. Identification of the BRAF V600E mutation in a patient with sclerosing pneumocytoma: A case report.
Jiang G; Zhang M; Tan Q; Lin S; Zeng Y; Liu C; Chen R; Zhou J
Lung Cancer; 2019 Nov; 137():52-55. PubMed ID: 31546071
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
Shimada Y; Tajima Y; Nagahashi M; Ichikawa H; Oyanagi H; Okuda S; Takabe K; Wakai T
J Surg Res; 2018 Dec; 232():72-81. PubMed ID: 30463788
[TBL] [Abstract][Full Text] [Related]
30. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
31. Rapid clinical mutational testing of
Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
[TBL] [Abstract][Full Text] [Related]
32. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer.
Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T
Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609
[TBL] [Abstract][Full Text] [Related]
33. DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer.
Jurmeister P; Schöler A; Arnold A; Klauschen F; Lenze D; Hummel M; Schweizer L; Bläker H; Pfitzner BM; Mamlouk S; Sers C; Denkert C; Stichel D; Frost N; Horst D; von Laffert M; Capper D
Mod Pathol; 2019 Jun; 32(6):855-865. PubMed ID: 30723296
[TBL] [Abstract][Full Text] [Related]
34. The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review.
Afrăsânie VA; Gafton B; Marinca MV; Alexa-Stratulat T; Miron L; Rusu C; Ivanov AV; Balan GG; Croitoru AE
J Gastrointestin Liver Dis; 2020 Jun; 29(2):251-256. PubMed ID: 32530992
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
36. Co-existence of BRAF V600E Gene Mutation in Tumor and Non-tumoral Surrounding Tissues in Colorectal Cancer.
Öztürk T; Toptaş-Hekimoğlu B; Eronat AP; Saygili N; Dağlar-Aday A; Başsüllü N; Türkmen I; Aydoğan HY; Bülbül G; Göksel S; Öztürk O; Isbir T
In Vivo; 2015; 29(5):577-84. PubMed ID: 26359417
[TBL] [Abstract][Full Text] [Related]
37. Primary Enteric Adenocarcinoma Lung with Mesenchymal Epithelial Transition Factor Amplification: A Case Report.
Shukla S; Pandey RK; Husain N; Srivastava A
Gulf J Oncolog; 2021 May; 1(36):76-78. PubMed ID: 35017140
[TBL] [Abstract][Full Text] [Related]
38. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
Paik PK; Arcila ME; Fara M; Sima CS; Miller VA; Kris MG; Ladanyi M; Riely GJ
J Clin Oncol; 2011 May; 29(15):2046-51. PubMed ID: 21483012
[TBL] [Abstract][Full Text] [Related]
40. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
